Most people who take Mounjaro get some side effects — and most of them are mild, digestive, and settle as the body adjusts. But "usually mild" isn't the whole story: a small number of effects genuinely need a doctor, and knowing the difference is what keeps treatment safe. This is the doctor-led guide for Ireland — what's common, what's serious, what the licensing data actually shows, and how supervised care manages each stage.
Quick answer (August 2026): the most common Mounjaro (tirzepatide) side effects in the EU licensing data are nausea, diarrhoea, vomiting, constipation and abdominal pain — each affecting more than 1 in 10 people, usually mild-to-moderate, and most noticeable in the weeks after a dose increase. Serious effects such as acute pancreatitis or gallbladder disease are much rarer but need prompt medical attention. Side effects are a major reason dose increases should be doctor-paced, not rushed.
Try the Slimbr weight loss plan
First month service fee just €49. If the doctor decides it's not suitable for you, your doctor consultation is free.
Why Mounjaro causes side effects at all
Mounjaro's active ingredient is tirzepatide, which acts on two gut-hormone receptors (GIP and GLP-1). The same mechanism that quietens appetite also slows how quickly the stomach empties — which is why almost every common side effect on the list is digestive. It's not a sign the medicine is "disagreeing" with you; it's the mechanism itself.
That mechanism link matters for expectations: in the EU regulator's assessment, the common effects were "generally mild or moderate in severity and occurred more often shortly after the dose was increased." Translation — the worst of it is usually temporary and dose-related, which is exactly why the pace of titration should be a clinical decision.
The very common side effects (more than 1 in 10 people)
From the European product information for Mounjaro, the side effects classed as very common are:
- Nausea — the signature GLP-1 effect, typically worst in the first days after starting or stepping up a dose.
- Diarrhoea — usually short-lived episodes rather than constant.
- Vomiting — less frequent than nausea, same pattern.
- Constipation — the flip side of slower digestion; often the most persistent of the group.
- Abdominal pain — usually crampy and passing (but see the red-flags section below for the version that isn't).
- Low blood sugar — mainly relevant when tirzepatide is combined with certain diabetes medicines (a sulphonylurea or insulin); it is not a typical feature of doctor-supervised weight-management use without those medicines.
The common ones (the leaflet's "up to 1 in 10" band)
One tier down in frequency: indigestion, bloating, burping, wind, acid reflux, reduced appetite beyond what's wanted, dizziness, fatigue, and injection-site reactions (redness or itching that settles). Individually minor, but worth knowing about in advance — a new symptom you expected is far less alarming than one you didn't.
Hair loss: less common than "up to 1 in 10" sounds — and linked to the weight loss itself, not the dose
The patient leaflet files hair loss under "common", and that word scares people. "Common" is a regulatory band that means anywhere from 1 in 100 to 1 in 10 — it is not a measured rate. The measured rate in the tirzepatide weight-management trials was about 5 in 100 (5% at 5 mg, 4% at 10 mg, 5% at 15 mg) versus 1 in 100 on placebo. Roughly 95 in 100 people did not report it, and not one person taking the medicine left the trials because of it.
What was reported was temporary shedding, not bald patches, and the licensing data links it to the weight reduction itself, not the dose (the rate was the same at 5 mg as at 15 mg). Losing a lot of weight quickly — by crash dieting, surgery or medication — pushes more hairs into a resting-and-shedding phase for a few months; in the trials it affected women far more than men (7.1% vs 0.5%) and generally settled while treatment continued. This is exactly why Slimbr is so insistent on losing weight at a steady, doctor-paced rate with enough protein. GLP-1 medicines are powerful enough to make a crash diet easy — and shedding hair to lose the weight in half the time is a bad trade.
What the adjustment period usually looks like
Did you know you can claim up to 75% back on your health insurance?
See how the claim works →The serious ones: rare, but know the red flags
These are uncommon (fewer than 1 in 100) to rare — but they are the reason weight-loss injections are prescription medicines and not supplements:
- Acute pancreatitis — the warning sign is persistent, severe abdominal pain, sometimes radiating to the back, with or without vomiting. This is not "a bit of cramping after dinner". If it happens, stop injecting and seek medical care the same day.
- Gallbladder problems (gallstones, inflammation) — a known risk that, in the trials, tracked with the amount of weight lost. Symptoms: pain under the right ribs, especially after fatty food, fever, or yellowing of skin/eyes.
- Dehydration affecting the kidneys — if vomiting or diarrhoea is heavy and you can't keep fluids down, that needs medical attention; in vulnerable people it can strain kidney function.
- Serious allergic reaction — rare; facial/throat swelling or breathing difficulty is an emergency (call 112/999).
In Ireland you can also report any suspected side effect directly to the medicines regulator, the HPRA, via the report form on hpra.ie — patient reports genuinely feed the safety data.
Try the Slimbr weight loss plan: first month service fee just €49 →
How doctors actually manage side effects
Most of the practical playbook is simple, and it's the same one our clinicians walk patients through:
Mounjaro vs the other injections: is it worse?
All the licensed weight-loss injections in Ireland — Mounjaro (tirzepatide), Wegovy (semaglutide) and Saxenda (liraglutide) — share the same core digestive side-effect profile, because they share the gut-hormone mechanism. The differences are individual more than chemical: some people tolerate one medicine noticeably better than another, which no one can fully predict in advance.
We've covered semaglutide's side effects separately, and our four-way comparison looks at how a clinician chooses between them. For the full picture of eligibility, dosing schedule and supervision in Ireland, see the complete Mounjaro Ireland guide.
The unsupervised-use problem
Everything above assumes one thing: a doctor who knows your history prescribed the medicine, set the pace, and is reachable when something feels wrong. That assumption fails for medication bought from unregulated sellers — where doses jump too fast, red flags get missed, and the "medicine" may not even be genuine.
Irish seizures of illegal weight-loss products rose sharply in 2025, and side effects from unverified products are a very different risk category. If you're comparing providers, our guide to verifying a weight-loss provider in 60 seconds covers the checks — or start with a service where an Irish-registered doctor is part of the programme: take the 60-second eligibility check.
Frequently asked questions
Do Mounjaro side effects go away?
For most people, yes — the common digestive effects are worst in the first weeks after starting or increasing a dose and settle as the body adjusts. Effects that persist or worsen are a reason to talk to your prescriber about pacing, not something to push through.
What is the most serious side effect of Mounjaro?
The one to know by name is acute pancreatitis — rare, but it needs same-day medical care. Its signature is persistent, severe abdominal pain (sometimes through to the back), quite different from ordinary crampy adjustment symptoms. Gallbladder disease and dehydration-related kidney strain are the other rare-but-serious ones.
Does everyone get nausea on Mounjaro?
No. Nausea is the most common effect — affecting more than 1 in 10 people in the licensing data — but that still means many people get little or none. Starting low and increasing slowly under medical supervision is the main way to keep it that way.
Does Mounjaro cause hair loss?
For most people, no. About 5 in 100 people in the tirzepatide weight-management trials reported temporary hair shedding, versus 1 in 100 on placebo — the leaflet's "common (up to 1 in 10)" wording is a regulatory band, not the measured rate. The licensing data links it to the weight reduction itself (the rate was the same at 5 mg and 15 mg), it affected women far more than men (7.1% vs 0.5%), nobody stopped treatment because of it, and it generally settled during continued treatment. Losing weight at a steady, doctor-paced rate with enough protein — not a crash diet — is how you make it less likely.
Should I stop Mounjaro if I get side effects?
Not on your own, unless it's an emergency (severe persistent abdominal pain, allergic reaction — seek urgent care). For everything else, contact your prescriber first: adjusting the dose pace resolves most problems, and stopping abruptly without a plan has its own downsides. This is exactly what medical supervision is for.
